3 results
primaryTo assess the safety and tolerability of multiple, once-daily oral doses of RDN-929 over 28 days in healthy older adult subjects and early symptomatic AD subjects.secondaryTo assess the plasma and CSF pharmacokinetics (PK) of RDN-929 in…
The primary objective of this study is to compare the overall survival (OS) associated with rAd-IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM…
To assess the efficacy of the BIHAP (AP® 5, Inreda Diabetic BV) using glucagon and insulin during a three-months period. It is hypothesized that treatment with BIHAP provides better glucose control than current diabetes treatment. Main parameter to…